U.S. Global Investors (USGI)’s Anika Therapeutics ANIK Stock Holding History

U.S. Global Investors (USGI)’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-15,000	Closed	-$618K	–	301
2015 Q1	$618K	Buy	+15,000	New	+$606K	0.17%	124

Other funds holding ANIK

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LCP

Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

U.S. Global Investors (USGI)'s ANIK Position: Q2 2015 in Review

U.S. Global Investors (USGI) sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 15,000 shares — an estimated $618K sold.

U.S. Global Investors (USGI) first reported a position in ANIK in Q1 2015 and held it in 1 quarter. The position peaked at $618K in Q1 2015. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

U.S. Global Investors (USGI) reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
U.S. Global Investors (USGI) sold 15,000 Anika Therapeutics shares in Q2 2015, an estimated $618K.
U.S. Global Investors (USGI) first reported a position in Anika Therapeutics in Q1 2015 and held it in 1 quarter.
U.S. Global Investors (USGI)'s Anika Therapeutics position peaked at $618K in Q1 2015.
136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on U.S. Global Investors (USGI)'s 13F filing for Q2 2015, filed 14 Aug 2015.